A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone?

The International Journal of Neuropsychopharmacology
João V NaniMirian A F Hayashi

Abstract

Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia (SCZ) patients compared to healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting SCZ was suggested. ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (N = 53) and antipsychotic-naïve first-episode psychosis (FEP) patients (N = 45), assessed at baseline (FEB-B) and also after 2-months (FEP-2M) of treatment with the atypical antipsychotic risperidone. ACE activity measurements showed significant differences among HC, FEP-B and FEP-2M groups (F = 5.356, df = 2, p = 0.005), as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, p = 0.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total PANSS (r = -0.131, p = 0.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, p = 0.392), but ACE activity levels differences observed between these groups were influenced by age. The importance of...Continue Reading

References

Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LaruelleR B Innis
Apr 20, 2005·Regulatory Peptides·Nidia BassoFelipe Inserra
May 10, 2007·Nature Protocols·Adriana K CarmonaEdward D Sturrock
Sep 25, 2007·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Maurício Silva de LimaFernando Madalena Volpe
Feb 8, 2013·Journal of Psychiatric Research·Ary GadelhaMirian A F Hayashi
Apr 12, 2013·CNS & Neurological Disorders Drug Targets·Amber L LaCrosse, M Foster Olive
May 17, 2013·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Gwan Gyu SongYoung Ho Lee
Jul 17, 2014·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Cinthia H HiguchiRodrigo A Bressan
Aug 22, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Gwan Gyu Song, Young Ho Lee
Jan 8, 2015·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Kelly K AndersonKwame J Mckenzie
Feb 27, 2015·Schizophrenia Research·Cristiano NotoElisa Brietzke
Aug 1, 2015·Journal of Psychiatric Research·Cristiano NotoElisa Brietzke
Oct 27, 2015·European Psychiatry : the Journal of the Association of European Psychiatrists·S ItoM Mizuno
Dec 20, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·J Elowe, P Conus
Jul 2, 2017·British Journal of Pharmacology·Colm M P O'TuathaighJohn L Waddington
Apr 18, 2018·Journal of Alzheimer's Disease : JAD·Sevil YasarMichelle C Carlson
Oct 16, 2018·Journal of Affective Disorders·Caroline Dal MasMirian A F Hayashi
Nov 18, 2018·Cellular and Molecular Neurobiology·Marianne O KleinRicardo G Correa
Dec 12, 2018·Psychiatry Research·Adrienne W Y LiEric Y H Chen
Dec 4, 2019·Neuroscience and Biobehavioral Reviews·Benjamín RodríguezMirian A F Hayashi

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
pharmacotherapy

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here